- Home
- DSM vs TVRD Comparison
DSM vs TVRD Comparison
Compare DSM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | TVRD |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 246.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DSM | TVRD |
|---|---|---|
| Price | $5.98 | $3.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 161.7K | 108.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.69 | $3.74 |
| 52 Week High | $6.05 | $43.65 |
Technical Indicators
Market Signals| Indicator | DSM | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 31.14 |
| Support Level | $5.93 | $3.83 |
| Resistance Level | $6.09 | $4.44 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.00 | 0.32 |
| Stochastic Oscillator | 54.00 | 24.74 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.